Citi analyst David Lebowitz opened a "negative Catalyst Watch" on shares of Blueprint Medicines given a view that the Ayvakit response data in February will likely add to doubts regarding the size of the market opportunity. Citi views the Ayvakit application for indolent systemic mastocytosis as being approvable but says questions regarding the size of the opportunity persist.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on BPMC:
- Blueprint Medicines’ Supplemental NDA for Ayvakit approved by FDA
- Wells Fargo upgrades Blueprint Medicines to Equal Weight with $41 price target
- Blueprint Medicines upgraded to Equal Weight from Underweight at Wells Fargo
- Blueprint Medicines initiated with a Buy at Needham
- Blueprint Medicines price target lowered to $53 from $58 at Barclays